Abstract 5908
Background
Gastric and GEJ cancers are one of the top four cancers in India with poor 5-year survival. Post ASCO 2017, we switched to docetaxel-based peri-operative chemotherapy (FLOT) which is the new standard of care. In this audit, we report the pathological response and toxicity of FLOT compared to our older standard (EOX/ECF).
Methods
We analysed our database of 118 patients with gastric or GEJ adenocarcinoma treated at our center from May 2011 to April 2019. 85 patients (72%) received perioperative chemotherapy with three pre-operative and three post-operative 3-week cycles of either EOX (50mg/m2 Epirubicin and 130mg/m2 Oxaliplatin on Day 1 plus 1250mg/m2 Capecitabine for 21 days) or ECF (50mg/m2 Epirubicin and 60mg/m2 Cisplatin on Day 1 plus 800mg/m2/day Fluorouracil as continuous intravenous infusion for 5 days). 33 patients (28%) received four pre-operative and four post-operative 2-week cycles of intravenous FLOT (50mg/m2 Docetaxel, 85mg/m2 Oxaliplatin, 200mg/m2 Leucovorin and 2600mg/m2 Fluorouracil as 24hr infusion on Day 1). We compared the toxicity, and pathological tumor response rates of patients on EOX/ECF and FLOT regimens.
Results
The patients were aged 30 to 73 years (Median 58 years) and 40 (34%) were women. 85 patients received either EOX/ECF and 33 received FLOT chemotherapy. 64 (75%) patients in EOX/ECF underwent gastrectomy among whom eight (12.5%) had pathological Tumour Regression Score (TRS) of 0 or 1. 24 (72%) patients in FLOT group have undergone gastrectomy of whom six (25%) had TRS of 0 or 1. 34 (40%) patients completed full EOX/ECF regimen while 20 (60%) completed full FLOT. The commonest reason for not completing the peri-operative chemotherapy was toxicity in EOX/ECF group (29%) and refusal to undergo surgery (21%) in the FLOT group. 15% patients did not complete FLOT chemotherapy due to toxicity.
Conclusions
FLOT regimen is a better tolerated perioperative therapy in Indian patients achieving higher pathological response compared to EOX/ECF regimen. The patients in both groups are currently on follow up to capture the relapse free survival duration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tanuj Chawla.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract